Skip to main content
    S

    STERIS plc (STE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $262.05
    -2.27 (-0.86%)

    Market Cap: $25.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    STERIS plc (STE) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    STERIS (STE) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, STERIS reported EPS of $2.94, above the $2.67 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    80%(32/40)
    Avg Surprise
    +4.53%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.80
    Range$2.78 - $2.83
    7 analysts
    EPS Estimate DriftChange to current
    90d ago$2.81-0.4%
    60d ago$2.81-0.1%
    30d ago$2.81-0.1%
    7d ago$2.80+0.0%
    Current$2.80
    Revenue Consensus
    $1.60B
    Range$1.59B - $1.61B
    7 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.18
    Range$3.07 - $3.34
    9 analysts
    Revenue Consensus
    $1.71B
    Range$1.57B - $1.84B
    9 analysts

    Next Report

    STE has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.7% above the $2.53 reported for the quarter ended Dec 31, 2025.

    STE Earnings Call

    The latest STE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, STE beat 32, missed 4 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $1.59B, up 8.9% from $1.46B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.94$2.67$2.66 - $2.70+10.11%Beat+19.0%60 up, 0 downNov 4, 2026$1.59B
    Jun 30, 2026$2.59$2.54$2.44 - $2.58+1.97%Beat+10.7%82 up, 2 downAug 5, 2026$1.49B
    Mar 31, 2026$2.83$2.85$2.81 - $2.90-0.70%Miss+3.3%71 up, 6 downMay 11, 2026$1.59B
    Dec 31, 2025$2.53$2.53$2.47 - $2.610.00%In line+9.1%82 up, 3 downFeb 4, 2026$1.50B
    Sep 30, 2025$2.47$2.38$2.31 - $2.42+3.78%Beat+15.4%80 up, 1 downNov 5, 2025$1.46B
    Jun 30, 2025$2.34$2.26$2.18 - $2.33+3.54%Beat+15.3%8N/AAug 6, 2025$1.39B
    Mar 31, 2025$2.74$2.60$2.57 - $2.61+5.38%Beat+6.2%70 up, 1 downMay 14, 2025$1.48B
    Dec 31, 2024$2.32$2.32$2.29 - $2.350.00%In line+4.5%72 up, 5 downFeb 5, 2025$1.37B
    Sep 30, 2024$2.14$2.13$2.10 - $2.16+0.47%Beat+3.4%70 up, 1 downNov 6, 2024$1.33B
    Jun 30, 2024$2.03$1.98$1.92 - $2.02+2.53%Beat+1.5%70 up, 1 downAug 6, 2024$1.28B
    Mar 31, 2024$2.58$2.41$2.20 - $2.42+7.05%Beat+12.2%70 up, 1 downMay 8, 2024$1.42B
    Dec 31, 2023$2.22$2.17$2.15 - $2.22+2.30%Beat+9.9%70 up, 0 downFeb 7, 2024$1.30B
    Sep 30, 2023$2.07$2.00$1.90 - $2.07+3.50%Beat+4.0%60 up, 0 downNov 7, 2023$1.24B
    Jun 30, 2023$2.00$1.86$1.80 - $1.91+7.53%Beat+5.3%60 up, 1 downAug 1, 2023$1.18B
    Mar 31, 2023$2.30$2.15$2.13 - $2.16+6.98%Beat+12.7%61 up, 0 downMay 10, 2023$963.26M
    Dec 31, 2022$2.02$2.19$2.17 - $2.26-7.76%Miss-4.7%60 up, 0 downFeb 8, 2023$1.22B
    Sep 30, 2022$1.99$1.98$1.93 - $2.04+0.51%Beat0.0%60 up, 0 downNov 9, 2022$1.20B
    Jun 30, 2022$1.90$1.90$1.86 - $2.000.00%In line+8.0%61 up, 0 downAug 2, 2022$1.16B
    Mar 31, 2022$2.04$2.02$2.00 - $2.04+0.99%Beat+25.2%50 up, 0 downMay 11, 2022$849.02M
    Dec 31, 2021$2.12$1.96$1.95 - $2.00+8.16%Beat+22.5%50 up, 1 downFeb 8, 2022$1.21B
    Sep 30, 2021$1.99$1.82$1.71 - $1.86+9.34%Beat+34.5%50 up, 0 downNov 2, 2021$1.20B
    Jun 30, 2021$1.76$1.49$1.43 - $1.52+18.12%Beat+34.4%5N/AAug 9, 2021$968.42M
    Mar 31, 2021$1.63$1.80$1.75 - $1.81-9.44%Miss-0.6%6N/AMay 18, 2021$873.53M
    Dec 31, 2020$1.73$1.54$1.41 - $1.58+12.34%Beat+19.3%6N/AFeb 2, 2021$808.92M
    Sep 30, 2020$1.48$1.27$1.21 - $1.34+16.54%Beat+12.1%6N/ANov 2, 2020$756.13M
    Jun 30, 2020$1.31$0.98$0.85 - $1.03+33.67%Beat+6.5%5N/AAug 3, 2020$668.93M
    Mar 31, 2020$1.64$1.58$1.51 - $1.62+3.80%Beat+7.2%4N/AMay 13, 2020$822.99M
    Dec 31, 2019$1.45$1.42$1.39 - $1.47+2.11%Beat+15.1%5N/AFeb 10, 2020$774.26M
    Sep 30, 2019$1.32$1.25$1.23 - $1.30+5.60%Beat+20.0%6N/ANov 4, 2019$736.84M
    Jun 30, 2019$1.23$1.11$1.08 - $1.12+10.81%Beat+23.0%7N/AAug 5, 2019$696.80M
    Mar 31, 2019$1.53$1.43$1.40 - $1.45+6.99%Beat+23.4%7N/AMay 13, 2019$768.21M
    Dec 31, 2018$1.26$1.25$1.20 - $1.30+0.80%Beat+12.5%8N/AFeb 11, 2019$696.24M
    Sep 30, 2018$1.10$1.09N/A+0.92%Beat+17.0%N/AN/ANov 6, 2018$678.96M
    Jun 30, 2018$1.00$0.99$0.95 - $1.03+1.01%Beat+17.6%8N/AAug 8, 2018$638.76M
    Mar 31, 2018$1.24$1.22$1.20 - $1.23+1.64%Beat+11.7%8N/AMay 9, 2018$715.97M
    Dec 31, 2017$1.12$1.07$1.04 - $1.11+4.67%Beat+14.3%8N/AFeb 7, 2018$661.90M
    Sep 30, 2017$0.94$0.94$0.92 - $1.000.00%In line+5.6%8N/ANov 1, 2017$634.16M
    Jun 30, 2017$0.85$0.80$0.78 - $0.82+6.25%Beat+7.6%8N/AAug 8, 2017$607.96M
    Mar 31, 2017$1.11$1.06N/A+4.72%Beat+23.3%N/AN/AMay 9, 2017$681.19M
    Dec 31, 2016$0.98$1.03N/A-4.85%Miss0.0%N/AN/AFeb 7, 2017$646.77M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Mar 31, 2026 was $10.17, up 10.2% from the year before. It was $3.77 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Mar 31, 2026$10.17+10.2%
    Mar 31, 2025$9.23+4.1%
    Mar 31, 2024$8.87+8.0%
    Mar 31, 2023$8.21+3.8%
    Mar 31, 2022$7.91+28.6%
    Mar 31, 2021$6.15+9.0%
    Mar 31, 2020$5.64+15.3%
    Mar 31, 2019$4.89+17.8%
    Mar 31, 2018$4.15+10.1%
    Mar 31, 2017$3.77N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,32510
    2026Q2Jun 30, 20263,0559
    2026Q1Mar 31, 20263,80612
    2025Q4Dec 31, 20253,80011
    2025Q3Sep 30, 20254,61611
    2025Q2Jun 30, 20253,41410
    2025Q1Mar 31, 20253,44010
    2024Q4Dec 31, 20243,3519

    2026Q3 Earnings Call

    Opening remarks

    Julie Winter Vice President, Investor Relations Thank you, Teck, and good morning, everyone. Speaking on today's call will be Karen Burton, our Senior Vice President and Chief Financial Officer, and Daniel A. Carestio, our President and Chief Executive Officer.

    Karen Burton Senior Vice President and Chief Financial Officer I do have a few words of caution before we open for comments. This webcast contains time-sensitive information that is only as of today. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. Some of the statements made during this review may be considered forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in STERIS' securities filings. The company does not undertake to update or revise any forward-looking statements as a result of new information or future events or developments. STERIS' SEC filings are available through the company and on our website. In addition, on today's call, non-GAAP financial measures, including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and free cash flow will be used. Additional information regarding these measures, including definitions, is available in our press release as well as reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency to supplemental financial information used by management and the board of directors in their financial analysis and operational decision-making. With those cautions, I will hand the call over to Dan for his remarks. Thank you, and good morning, everyone. It is my pleasure to be with you this morning to review the highlights of our third-quarter performance from continuing operations. For the third quarter, total as-reported revenue grew 9%. Constant currency organic revenue grew 8% in the quarter, driven by volume as well as 200 basis points of price. Gross margin for the quarter declined 70 basis points compared with the prior year to 43.9%. Positive price and productivity, primarily driven by volume, were more than offset by increased tariffs and inflation. EBIT margin decreased 40 basis points to 22.9% of revenue compared with last year, mainly driven by the decline in gross margin, which was somewhat mitigated by operating expense discipline. The adjusted effective tax rate in the quarter was 24.2%, a small decline from 24.5% in the third quarter of last year. The year-over-year decrease was driven primarily by changes in geographic mix. Adjusted net income from continuing operations in the quarter was $249.4 million. Earnings per diluted share from continuing operations were $2.53, a 9% increase over the prior year. Capital expenditures for the first nine months of fiscal 2026 totaled $278.8 million, and depreciation and amortization totaled $363.1 million.

    Frequently Asked Questions About STE

    When is STERIS's next earnings date?

    STERIS's next earnings report is expected for Feb 2, 2027.

    Did STE beat earnings estimates last quarter?

    Yes. STERIS reported EPS of $2.94 for the quarter ended Sep 30, 2026, above the $2.67 estimate, a 10.11% surprise.

    What EPS do analysts expect from STE next quarter?

    The consensus EPS estimate for STERIS for the quarter ending Dec 31, 2026 is $2.80 from 7 analysts, with estimates from $2.78 to $2.83.

    How often does STE beat earnings estimates?

    STERIS beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.01%.